- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02442531
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- University Hospital Leuven
-
-
-
-
-
Amsterdam, Netherlands
- VUMC Amsterdam
-
Groningen, Netherlands
- UMC Groningen
-
Rotterdam, Netherlands
- Erasmus Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years old
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Estimated life expectancy of at least 12 weeks
Ability and willingness to give written informed consent and to comply with the requirements of the study
For Part 1:
Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive solid tumours that are refractory to standard therapy or for whom no standard therapy exists and with measurable or evaluable disease according to RECIST 1.1.
For Part 2:
- Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive cancer with measurable disease according to RECIST 1.1 of a histological type that are refractory to standard therapy or for whom no standard therapy exists and where treatment with a taxane is an appropriate treatment option.
Exclusion Criteria:
- Less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy or systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), and less than 6 weeks for nitrosoureas and mitomycin C prior to Cycle 1 Day 1.
- Current or recent (within 4 weeks prior to Cycle 1 Day 1) treatment with another Investigational Product or participation in another investigational interventional study.
- Symptomatic brain metastases.
- Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) that have not resolved to ≤ grade 2 (as defined by CTCAE version 4.03).
Inadequate bone marrow function at screening as evidenced by any of the following:
- Absolute Neutrophil Count (ANC) < 1.5 x 109/L.
- Platelet count < 100 x 109/L.
- Haemoglobin < 6.0 mmol/L (< 9.6 g/dL). The patient should not have received a transfusion or growth factors for these abnormalities in the 7 days prior to Cycle 1 Day 1.
- Serum (total) bilirubin > 1.5 x the Upper Limit of Normal (ULN) for the institution if no liver metastases (> 2 x ULN in patients with liver metastases).
- AST or ALT > 2.5 x ULN if no liver metastases (> 5x ULN in patients with liver metastases).
- Alkaline phosphatase levels > 2.5 x ULN if no liver metastases (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
- Increased plasma prothrombin time or International Normalized Ratio (INR), consequence of reduced hepatic production of Vitamin K.
- Hepatitis B surface antigen or hepatitis C positivity with abnormal liver function tests.
Medical history of:
- Nonalcoholic steatohepatitis (NASH).
- History of human immunodeficiency virus (HIV) antibody positive or use of antiretroviral therapy.
- Alcoholic and autoimmune hepatitis.
- Ischemic hepatitis, Cardiovascular dysfunction or impaired liver oxygenation, including hypotension or right heart failure.
- Serum creatinine > 1.5 x ULN.
- Estimated Glomerular Filtration Rate of < 50 mL/min/1.73m2 calculated by Modification of Diet in Renal Disease (MDRD) formula or creatinine clearance of < 50 mL/min calculated by Cockcroft-Gault.
- Stroke within 6 months prior to Cycle 1 Day 1.
- Transient Ischemic Attack (TIA) within 6 months prior to Cycle 1 Day 1.
- Myocardial infarction within 6 months prior to Cycle 1 Day 1.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure at screening.
- Serious cardiac arrhythmia requiring medication.
- Patients who are pregnant or breastfeeding.
- Absence of effective means of contraception in female patients of childbearing potential (defined as <2 years after last menstruation and not surgically sterile) or in male patients who are not surgically sterile and who have female partners of childbearing potential.
- Major surgical procedure (including open biopsy and excluding central line intravenous catheter) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- Grade ≥2 motor or sensory neuropathy symptoms (as defined by CTCAE version 4.03).
- Known hypersensitivity to any of the Investigational Product's excipients or taxanes.
- History of drug or alcohol abuse in the opinion of the investigator within 3 years before screening.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk for treatment-related complications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CriPec® docetaxel
Docetaxel containing nanoparticle
|
-3 weekly IV dose.
Dose escalation; start dose 15 mg/m2.
Number of cycles: 6 or until progression or unacceptable toxicity develops
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) as a measure of safety and tolerability.
Time Frame: 9 months
|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of clinical laboratory abnormalities as a measure of safety and tolerability.
Time Frame: 9 months
|
Part 1: Incidence of laboratory abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities as a measure of safety and tolerability.
Time Frame: 9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1.
Time Frame: 9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Time Frame: 9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Time Frame: 9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 1 and 2: Pharmacokinetic profile of CriPec® docetaxel following IV infusion
Time Frame: First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Pharmacokinetic parameters such as time to peak concentration (Tmax), peak concentration (Cmax), volume of distribution (Vd), half life (t1/2), total body clearance (CL) and area under the concentration-time curve (AUC) will be determined using plasma concentration data.
|
First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Early signs of anti-tumor efficacy (overall response rate [ORR]) of CriPec® docetaxel
Time Frame: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Early signs of anti-tumor efficacy (duration of response) of CriPec® docetaxel
Time Frame: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-CL01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on CriPec® docetaxel
-
Amsterdam UMC, location VUmcCristal TherapeuticsCompleted
-
Cristal TherapeuticsCompletedCancer | Ovarian CancerNetherlands, Belgium, United Kingdom
-
Hoffmann-La RocheCompletedBreast CancerChina, United States, South Africa, Russian Federation, Thailand, Bosnia and Herzegovina, Czech Republic, India, Poland
-
National University Hospital, SingaporeCompleted
-
Merck Sharp & Dohme LLCTerminatedBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer
-
Korean Breast Cancer Study GroupUnknownMetastatic Breast Cancer | Recurrent Breast CancerKorea, Republic of
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZenecaCompletedNon-Small Cell Lung CancerUnited States
-
Hospira, now a wholly owned subsidiary of PfizerCompletedCancerUnited Kingdom, Russian Federation
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLeukemiaUnited States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand